Streetbeat News

AVRO

AvroBio Inc

Employees

95

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.

Open

1.43

Mkt cap

5.2M

Volume

204K

High

1.44

P/E Ratio

0.17

52-wk high

19.80

Low

1.38

Div yield

N/A

52-wk low

1.38

Trading for AVRO was halted at 7:50:00 p.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:50 pm

AVROBIO shareholders have approved a reverse stock split at a ratio ranging between 1:3 and 1:30.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 8:35 pm

AVROBIO's stock price is trading lower following the announcement that the company will acquire all outstanding equity interests of Tectonic Therapeutic.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 2:29 pm

Trading for AVRO has resumed at 8:25 AM ET after a temporary halt. The halt status update included news and resumption times for the stock.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 1:25 pm

AVROBIO, Inc. (AVRO) has announced an all-stock transaction to acquire 100% of the outstanding equity interests of Tectonic Therapeutic. The merger will result in AVROBIO expanding its pipeline with Tectonic's innovative technology platform.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 1:04 pm

Trading on AVRO has been halted at 7:55 a.m. ET due to pending news. The halt is in place to manage market orderliness and investor protection pending the release of material information.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 12:55 pm

Mizuho analyst Uy Ear has downgraded Avrobio (NASDAQ:AVRO) from Buy to Neutral and reduced the price target from $5 to $2.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:36 pm

Wells Fargo analyst Yanan Zhu has maintained an Overweight rating on Avrobio (NASDAQ:AVRO) but lowered the price target from $2.5 to $2.

Portfolio Pulse from Benzinga Newsdesk

July 13, 2023 | 11:56 am

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Healthcare Triangle (HCTI), Recursion Pharmaceuticals (RXRX), Petros Pharma (PTPI), Avrobio (AVRO), InspireMD (NSPR), and Freeline Therapeutics (FRLN). Losers included Silk Road Medical (SILK), CytoMed Therapeutics (GDTC), Adial Pharmaceuticals (ADIL), Biodexa Pharmaceuticals (BDRX), T2 Biosystems (TTOO), and Brookdale Senior Living (BKD).

Portfolio Pulse from Benzinga Insights

July 12, 2023 | 5:37 pm

The article lists the stocks that gained and lost the most during Wednesday's mid-day trading session. Among the gainers were Healthcare Triangle, Ault Alliance, and Recursion Pharmaceuticals, which saw significant increases due to various positive developments. On the other hand, PainReform, CBL International, and Katapult Holdings were among the biggest losers, with their stocks declining due to various negative developments.

Portfolio Pulse from Lisa Levin

July 12, 2023 | 4:53 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.